{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang YY"],"funding":["NINDS NIH HHS","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["13254-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC23773"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["95(22)"],"pubmed_abstract":["Paraneoplastic opsoclonus myoclonus ataxia (POMA) is a neurologic disorder thought to be mediated by an autoimmune attack against onconeural disease antigens that are expressed by gynecologic or lung tumors and by neurons. One POMA disease antigen, termed Nova-1, has been identified as a neuron-specific KH-type RNA-binding protein. Nova-1 expression is restricted to specific regions of the central nervous system, primarily the hindbrain and ventral spinal cord, which correlate with the predominantly motor symptoms in POMA. However, POMA antisera recognize antigens that are widely expressed in both caudal and rostral regions of the central nervous system, and some patients develop cognitive symptoms. We have used POMA antisera to clone a cDNA encoding a second POMA disease antigen termed No"],"journal":["Proceedings of the National Academy of Sciences of the United States of America"],"pubmed_title":["The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia."],"pmcid":["PMC23773"],"funding_grant_id":["CA 09673-18","R01 NS34389","2T32 GM07739"],"pubmed_authors":["Yang YY","Darnell RB","Yin GL"],"additional_accession":[]},"is_claimable":false,"name":"The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia.","description":"Paraneoplastic opsoclonus myoclonus ataxia (POMA) is a neurologic disorder thought to be mediated by an autoimmune attack against onconeural disease antigens that are expressed by gynecologic or lung tumors and by neurons. One POMA disease antigen, termed Nova-1, has been identified as a neuron-specific KH-type RNA-binding protein. Nova-1 expression is restricted to specific regions of the central nervous system, primarily the hindbrain and ventral spinal cord, which correlate with the predominantly motor symptoms in POMA. However, POMA antisera recognize antigens that are widely expressed in both caudal and rostral regions of the central nervous system, and some patients develop cognitive symptoms. We have used POMA antisera to clone a cDNA encoding a second POMA disease antigen termed No","dates":{"release":"1998-01-01T00:00:00Z","publication":"1998 Oct","modification":"2025-04-26T23:41:53.544Z","creation":"2019-03-27T00:17:51Z"},"accession":"S-EPMC23773","cross_references":{"pubmed":["9789075"],"doi":["10.1073/pnas.95.22.13254"]}}